A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings

Theodore A. Kastner, Kevin K. Walsh

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

This study retrospectively examined the efficacy of the atypical antipsychotic risperidone in people with developmental disabilities living in institutional settings. Specifically, this study examined the impact of risperidone on clinical global impression (CGI) ratings of medical/psychiatric and behavioral status and other clinical measures. The study collected data from 294 individuals receiving either risperidone or haloperidol, alone or in combination with other psychotropic medications, from a population residing in several state-run, ICF/MR-certified developmental centers in one state. Comparisons were made on retrospective data between those receiving risperidone and those receiving haloperidol on several measures based on intensive record reviews. Clinical characteristics of subjects were related to psychotropic medications and specifically to dose ranges. Significant differences were obtained on both medical and behavioral CGI measures between the risperidone and haloperidol groups. Implications of these and other findings are discussed.

Original languageEnglish (US)
Pages (from-to)10-20
Number of pages11
JournalMental Health Aspects of Developmental Disabilities
Volume7
Issue number1
StatePublished - Jan 1 2004

Keywords

  • Atypical antipsychotics
  • Clinical global impressions
  • Developmental disabilities
  • Institutional settings
  • Intellectual disability
  • Mental retardation
  • Psychiatric disorder

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'A Retrospective Analysis of the Efficacy of Risperidone in People with Developmental Disabilities Living in Institutional Settings'. Together they form a unique fingerprint.

  • Cite this